373 related articles for article (PubMed ID: 25737449)
1. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.
Li Y; Pierce BG; Wang Q; Keck ZY; Fuerst TR; Foung SK; Mariuzza RA
J Biol Chem; 2015 Apr; 290(16):10117-25. PubMed ID: 25737449
[TBL] [Abstract][Full Text] [Related]
2. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies.
Pantua H; Diao J; Ultsch M; Hazen M; Mathieu M; McCutcheon K; Takeda K; Date S; Cheung TK; Phung Q; Hass P; Arnott D; Hongo JA; Matthews DJ; Brown A; Patel AH; Kelley RF; Eigenbrot C; Kapadia SB
J Mol Biol; 2013 Jun; 425(11):1899-1914. PubMed ID: 23458406
[TBL] [Abstract][Full Text] [Related]
3. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
J Virol; 2018 May; 92(9):. PubMed ID: 29467319
[TBL] [Abstract][Full Text] [Related]
4. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
5. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423.
Keck ZY; Angus AG; Wang W; Lau P; Wang Y; Gatherer D; Patel AH; Foung SK
PLoS Pathog; 2014 Aug; 10(8):e1004297. PubMed ID: 25122476
[TBL] [Abstract][Full Text] [Related]
6. Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422.
Sandomenico A; Leonardi A; Berisio R; Sanguigno L; Focà G; Focà A; Ruggiero A; Doti N; Muscariello L; Barone D; Farina C; Owsianka A; Vitagliano L; Patel AH; Ruvo M
J Virol; 2016 Jan; 90(7):3745-59. PubMed ID: 26819303
[TBL] [Abstract][Full Text] [Related]
7. Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33.
Kong L; Giang E; Nieusma T; Robbins JB; Deller MC; Stanfield RL; Wilson IA; Law M
J Virol; 2012 Dec; 86(23):13085-8. PubMed ID: 22973046
[TBL] [Abstract][Full Text] [Related]
8. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.
Potter JA; Owsianka AM; Jeffery N; Matthews DJ; Keck ZY; Lau P; Foung SK; Taylor GL; Patel AH
J Virol; 2012 Dec; 86(23):12923-32. PubMed ID: 22993159
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.
Kong L; Giang E; Robbins JB; Stanfield RL; Burton DR; Wilson IA; Law M
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9499-504. PubMed ID: 22623528
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.
Tarr AW; Owsianka AM; Timms JM; McClure CP; Brown RJ; Hickling TP; Pietschmann T; Bartenschlager R; Patel AH; Ball JK
Hepatology; 2006 Mar; 43(3):592-601. PubMed ID: 16496330
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
[TBL] [Abstract][Full Text] [Related]
12. Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.
Meola A; Tarr AW; England P; Meredith LW; McClure CP; Foung SK; McKeating JA; Ball JK; Rey FA; Krey T
J Virol; 2015 Feb; 89(4):2170-81. PubMed ID: 25473061
[TBL] [Abstract][Full Text] [Related]
13. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
14. Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412-425 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles.
Czarnota A; Offersgaard A; Owsianka A; Alzua GP; Bukh J; Gottwein JM; Patel AH; Bieńkowska-Szewczyk K; Grzyb K
Microbiol Spectr; 2023 Jan; 11(2):e0254622. PubMed ID: 36719195
[TBL] [Abstract][Full Text] [Related]
15. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.
Urbanowicz RA; Wang R; Schiel JE; Keck ZY; Kerzic MC; Lau P; Rangarajan S; Garagusi KJ; Tan L; Guest JD; Ball JK; Pierce BG; Mariuzza RA; Foung SKH; Fuerst TR
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651366
[TBL] [Abstract][Full Text] [Related]
16. Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.
Rodrigo C; Walker MR; Leung P; Eltahla AA; Grebely J; Dore GJ; Applegate T; Page K; Dwivedi S; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Luciani F; Lloyd AR; Bull RA;
Infect Genet Evol; 2017 Apr; 49():88-96. PubMed ID: 28065804
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope.
Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021
[TBL] [Abstract][Full Text] [Related]
18. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
Ruwona TB; Giang E; Nieusma T; Law M
J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
[TBL] [Abstract][Full Text] [Related]
19. Junctional and somatic hypermutation-induced CX
Yi C; Xia J; He L; Ling Z; Wang X; Yan Y; Wang J; Zhao X; Fan W; Sun X; Zhang R; Ye S; Zhang R; Xu Y; Ma L; Zhang Y; Zhou H; Huang Z; Niu J; Long G; Lu J; Zhong J; Sun B
Cell Mol Immunol; 2021 Mar; 18(3):675-685. PubMed ID: 32235917
[TBL] [Abstract][Full Text] [Related]
20. HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development.
Ströh LJ; Krey T
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
